Chief R&D Officer (Oncology), Innovent Biologics
Appears in 3 stories
Leading IBI3001 development and the company's AD C pipeline
Innovent Biologics presented the first clinical data for IBI3001, an EGFR/B7H3 bispecific antibody-drug conjugate (ADC, a targeted drug carrying a chemotherapy payload), at the 2026 European Society for Medical Oncology (ESMO) congress. Of 57 patients who received the drug, 78.9% had two or more prior treatment lines. Among 53 patients evaluable for response, 30.2% responded and 88.7% had disease control.
Updated 2 days ago
Oversees IBI354 Phase 3 development including HeriCare-Breast01 and HeriCare-Ovarian01
Innovent presented Phase 2 results at the European Society for Medical Oncology (ESMO) congress on October 24. The data show its experimental HER2-targeting antibody-drug conjugate (ADC), IBI354, plus pertuzumab produced a 95% confirmed response rate in patients with unresectable, locally advanced or metastatic HER2-positive breast cancer. That is 19 of 20 patients, and none developed interstitial lung disease (ILD), a lung inflammation that is a known risk with trastuzumab deruxtecan (Enhertu).
Leading the drug's development program
Advanced gastric cancer that returns after treatment usually kills within about six months. On June 4, 2026, Chinese biotech Innovent Biologics said its drug had slowed that clock in a late-stage trial.
Updated Jun 4
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
